Swine influenza virus (SIV) is a fast-evolving viral pathogen in pig populations. However, commercial vaccines, based on inactivated viruses, cannot provide complete protection with induced humoral immunity only and require frequent updates to fight against current isolates. A DNA vaccine delivering conservative epitopes was designed in this study in the hope of meeting the need. In this study, a B-cell epitope (HA2.30-130), a quadruplicated Th-cell epitope (NP55-69), and a quadruplicated CTL epitope (NP147-158) were fused separately to the C-terminal of VP22c gene in the modified pcDNA3.1 plasmid. The expression of epitopes was confirmed by in vitro transfection of 293FT cells. The DNA vaccine administered intramuscularly stimulated epitope-specific immunity against the two T-cell epitopes in all ten mice before the virus challenge. Only two out of ten mice were ELISA positive against the B-cell epitope. All vaccinated mice survived a lethal dose of virus challenge, while all mice in the challenge control group died. The DNA vaccine delivering epitopes in this study showed promising protection against influenza virus in an animal model; however, more work needs to be done to evaluate the best conserved protective epitopes which can be applied in developing a universal DNA vaccine.
Get full access to this article
View all access options for this article.
References
1.
BentonKA, MisplonJA, LoCY, BrutkiewiczRR, PrasadSA, and EpsteinSL. 2001. Heterosubtypic immunity to influenza A virus in mice lacking IgA, all Ig, NKT cells, or gamma delta T cells. J Immunol, 2001; 166:7437–7445.
2.
BommakantiG, CitronMP, HeplerRW, et al.Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge. Proc Natl Acad Sci USA, 2010; 107:13701–13706.
3.
BotA, ReichlinA, IsobeH, BotS, SchulmanJ, YokoyamaWM, and BonaCA. Cellular mechanisms involved in protection and recovery from influenza virus infection in immunodeficient mice. J Virol, 1996; 70:5668–5672.
4.
ChoiT, M HuangM, C GormanC, and JaenischR. A generic intron increases gene expression in transgenic mice. Mol Cell Biol, 1991; 11:3070–3074.
5.
ChristensenJP, DohertyPC, BranumKC, and RiberdyJM. Profound protection against respiratory challenge with a lethal H7N7 influenza A virus by increasing the magnitude of CD8(+) T-cell memory. J Virol, 2000; 74:11690–11696.
6.
CoxRJ, BrokstadKA, and OgraP. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol, 2004; 59:1–15.
7.
DeliyannisG, JacksonDC, EdeNJ, et al.2002. Induction of long-term memory CD8(+) T cells for recall of viral clearing responses against influenza virus. J Virol, 2002; 76:4212–4221.
8.
DeliyannisG, KedzierskaK, LauYF, et al.Intranasal lipopeptide primes lung-resident memory CD8+ T cells for long-term pulmonary protection against influenza. Eur J Immunol, 2006; 36:770–778.
9.
EkiertDC, BhabhaG, ElsligerMA, et al.Antibody recognition of a highly conserved influenza virus epitope. Science, 2009; 324:246–251.
10.
EkiertDC, FriesenRH, BhabhaG, et al.A highly conserved neutralizing epitope on group 2 influenza A viruses. Science, 2011; 333:843–850.
11.
EpsteinSL, LoCY, MisplonJA, and BenninkJR. Mechanism of protective immunity against influenza virus infection in mice without antibodies. J Immunol, 1998; 160:322–327.
12.
EpsteinSL, LoCY, MisplonJA, et al.Mechanisms of heterosubtypic immunity to lethal influenza A virus infection in fully immunocompetent, T cell-depleted, beta2-microglobulin-deficient, and J chain-deficient mice. J Immunol, 1997; 158:1222–1230.
13.
GocnikM, FislovaT, SladkovaT, MuchaV, KostolanskyF, and VareckovaE. Antibodies specific to the HA2 glycopolypeptide of influenza A virus haemagglutinin with fusion-inhibition activity contribute to the protection of mice against lethal infection. J Gen Virol, 2007; 88:951–955.
14.
GuoH, SantiagoF, LambertK, TakimotoT, and TophamDJ. T cell-mediated protection against lethal 2009 pandemic H1N1 influenza virus infection in a mouse model. J Virol, 2011; 85:448–455.
15.
HillaireML, van TrierumSE, KreijtzJH, et al.Cross-protective immunity against influenza pH1N1 2009 viruses induced by seasonal influenza A (H3N2) virus is mediated by virus-specific T-cells. J Gen Virol, 2011; 92:2339–2349.
16.
JeonSH, Ben-YedidiaT, and ArnonR. Intranasal immunization with synthetic recombinant vaccine containing multiple epitopes of influenza virus. Vaccine, 2002; 20:2772–2780.
17.
KozakM. At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells. J Mol Biol, 1987; 196:947–950.
18.
LeviR, and ArnonR. Synthetic recombinant influenza vaccine induces efficient long-term immunity and cross-strain protection. Vaccine, 1996; 14:85–92.
19.
LiuW, and ChenYH. High epitope density in a single protein molecule significantly enhances antigenicity as well as immunogenicity: A novel strategy for modern vaccine development and a preliminary investigation about B cell discrimination of monomeric proteins. Eur J Immunol, 2006; 35:505–514.
20.
LuJ, WettsteinPJ, HigashimotoY, AppellaE, and CelisE. TAP-independent presentation of CTL epitopes by Trojan antigens. J Immunol, 2001; 166:7063–7071.
21.
LuJ, HigashimotoY, AppellaE, and CelisE. Multiepitope Trojan antigen peptide vaccines for the induction of antitumor CTL and Th immune responses. J Immunol, 2004; 172:4575–4582.
22.
LukacherAE, BracialeVL, and BracialeTJ. In vivo effector function of influenza virus-specific cytotoxic T lymphocyte clones is highly specific. J Exp Med, 1984; 160:814–826.
23.
MaW, and RichtJA. Swine influenza vaccines: Current status and future perspectives. Anim Health Res Rev, 2010; 11:81–96.
24.
NakayamaK. Furin: A mammalian subtilisin/Kex2p-like endoprotease involved in processing of a wide variety of precursor proteins. Biochem J, 1997; 327:625–635.
25.
OkunoY, IsegawaY, SasaoF, and UedaS. A common neutralizing epitope conserved between the hemagglutinins of influenza A virus H1 and H2 strains. J Virol, 1993; 67:2552–2558.
26.
OlafsdottirG, SvanssonV, IngvarssonS, MartiE, and TorsteinsdottirS. In vitro analysis of expression vectors for DNA vaccination of horses: The effect of a Kozak sequence. Acta Vet Scand, 2008; 50:44.
27.
OlsenCW. DNA vaccination against influenza viruses: A review with emphasis on equine and swine influenza. Vet Microbiol, 2000; 74:149–164.
28.
PalmiterRD, SandgrenEP, AvarbockMR, AllenDD, and BrinsterRL. Heterologous introns can enhance expression of transgenes in mice. Proc Natl Acad Sci USA, 1991; 88:478–482.
29.
RichtJA, LagerKM, ClouserDF, SpackmanE, SuarezDL, and YoonKY. Real-time reverse transcription-polymerase chain reaction assays for the detection and differentiation of North American swine influenza viruses. J Vet Diagn Invest, 2004; 16:367–373.
30.
ShopeRE. The etiology of swine influenza. Science, 1931; 73:214–215.
31.
StanekovaZ, and VareckovaE. Conserved epitopes of influenza A virus inducing protective immunity and their prospects for universal vaccine development. Virol J, 2010; 7:351.
32.
SteelJ, LowenAC, WangTT, et al.Influenza virus vaccine based on the conserved hemagglutinin stalk domain. MBio, 2010; 1.
33.
SuiJ, HwangWC, PerezS, et al.Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat Struct Mol Biol, 2009; 16:265–273.
34.
TamuraS, TanimotoT, and KurataT. Mechanisms of broad cross-protection provided by influenza virus infection and their application to vaccines. Jpn J Infect Dis, 2005; 58:195–207.
35.
TaoP, LuoM, PanR, LingD, ZhouS, TienP, and PanZ. Enhanced protective immunity against H5N1 influenza virus challenge by vaccination with DNA expressing a chimeric hemagglutinin in combination with an MHC class I-restricted epitope of nucleoprotein in mice. Antiviral Res, 2009; 81:253–260.
36.
TaylorPM, and AskonasBA. Influenza nucleoprotein-specific cytotoxic T-cell clones are protective in vivo. Immunology, 1986; 58:417–420.
37.
Van ReethK, BrownIH, and OlsenCW. Influenza virus. In: Diseases of Swine, 10th Ed. 557-71. ZimmermanJJ, KarrikerLA, RamirezA, SchwartzKJ, StevensonGW. (eds.) John Wiley & Sons, Inc, Iowa. 2012, pp. 557–571.
38.
VincentAL, MaW, LagerKM, JankeBH, and RichtJA. Swine influenza viruses. A North American perspective. Adv Virus Res, 2008; 72:127–154.
39.
WangS, TaaffeJ, ParkerC, et al.2006. Hemagglutinin (HA) proteins from H1 and H3 serotypes of influenza A viruses require different antigen designs for the induction of optimal protective antibody responses as studied by codon-optimized HA DNA vaccines. J Virol, 2006; 80:11628–11637.
40.
WangTT, TanGS, HaiR, PicaN, PetersenE, MoranTM, and PaleseP. Broadly protective monoclonal antibodies against H3 influenza viruses following sequential immunization with different hemagglutinins. PLoS Pathog, 2010; 6:e1000796.
41.
WangTT, TanGS, HaiR, et al.Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes. Proc Natl Acad Sci USA, 2010; 107:18979–18984.
42.
WeiH, LenzSD, ThompsonDH, and PogranichniyRM. DNA-vaccine platform development against H1N1 subtype of swine influenza A viruses. Viral Immunol, 2012; 25:297–305.
43.
WellsMA, EnnisFA, and AlbrechtP. Recovery from a viral respiratory infection. II. Passive transfer of immune spleen cells to mice with influenza pneumonia. J Immunol, 1981; 126:1042–1046.
44.
WHO. WHO Manual on Animal Influenza Diagnosis and Surveillance. In: World Health Organization, 2012.
45.
WrammertJ, KoutsonanosD, LiGM, et al.Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J Exp Med, 2011; 208:181–193.
46.
XuR, McBrideR, PaulsonJC, BaslerCF, and WilsonIA. Structure, receptor binding, and antigenicity of influenza virus hemagglutinins from the 1957 H2N2 pandemic. J Virol, 2010; 84:1715–1721.
47.
YapKL, AdaGL, and McKenzieIF. Transfer of specific cytotoxic T lymphocytes protects mice inoculated with influenza virus. Nature, 1978; 273:238–239.
48.
ZhaoG, LinY, DuL, et al.An M2e-based multiple antigenic peptide vaccine protects mice from lethal challenge with divergent H5N1 influenza viruses. Virol J, 2010; 7:9.
49.
ZhaoG, DuL, XiaoW, et al.Induction of protection against divergent H5N1 influenza viruses using a recombinant fusion protein linking influenza M2e to Onchocerca volvulus activation associated protein-1 (ASP-1) adjuvant. Vaccine, 2010; 28:7233–7240.
50.
ZhengCF, BrownlieR, HuangDY, BabiukLA, and van Drunen Littel-van den HurkS. Intercellular trafficking of the major tegument protein VP22 of bovine herpesvirus-1 and its application to improve a DNA vaccine. Arch Virol, 2006; 151:985–993.
